BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 12738716)

  • 41. Radioimmunotherapy of patients with small-volume tumors using iodine-131-labeled anti-CEA monoclonal antibody NP-4 F(ab')2.
    Juweid ME; Sharkey RM; Behr T; Swayne LC; Dunn R; Siegel J; Goldenberg DM
    J Nucl Med; 1996 Sep; 37(9):1504-10. PubMed ID: 8790202
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma.
    Chong G; Lee FT; Hopkins W; Tebbutt N; Cebon JS; Mountain AJ; Chappell B; Papenfuss A; Schleyer P; U P; Murphy R; Wirth V; Smyth FE; Potasz N; Poon A; Davis ID; Saunder T; O'keefe GJ; Burgess AW; Hoffman EW; Old LJ; Scott AM
    Clin Cancer Res; 2005 Jul; 11(13):4818-26. PubMed ID: 16000579
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.
    Gimsing P; Hansen M; Knudsen LM; Knoblauch P; Christensen IJ; Ooi CE; Buhl-Jensen P
    Eur J Haematol; 2008 Sep; 81(3):170-6. PubMed ID: 18510700
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A first-in-human study of conatumumab in adult patients with advanced solid tumors.
    Herbst RS; Kurzrock R; Hong DS; Valdivieso M; Hsu CP; Goyal L; Juan G; Hwang YC; Wong S; Hill JS; Friberg G; LoRusso PM
    Clin Cancer Res; 2010 Dec; 16(23):5883-91. PubMed ID: 20947515
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Superantigen-targeted therapy: phase I escalating repeat dose trial of the fusion protein PNU-214565 in patients with advanced gastrointestinal malignancies.
    Alpaugh RK; Schultz J; McAleer C; Giantonio BJ; Persson R; Burnite M; Nielsen SE; Vitek L; Persson B; Weiner LM
    Clin Cancer Res; 1998 Aug; 4(8):1903-14. PubMed ID: 9717818
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The human antimouse immunoglobulin response and the anti-idiotypic network have no influence on clinical outcome in patients with minimal residual colorectal cancer treated with monoclonal antibody CO17-1A.
    Gruber R; van Haarlem LJ; Warnaar SO; Holz E; Riethmüller G
    Cancer Res; 2000 Apr; 60(7):1921-6. PubMed ID: 10766181
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma.
    Mulligan T; Carrasquillo JA; Chung Y; Milenic DE; Schlom J; Feuerstein I; Paik C; Perentesis P; Reynolds J; Curt G
    Clin Cancer Res; 1995 Dec; 1(12):1447-54. PubMed ID: 9815943
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma.
    Posey JA; Ng TC; Yang B; Khazaeli MB; Carpenter MD; Fox F; Needle M; Waksal H; LoBuglio AF
    Clin Cancer Res; 2003 Apr; 9(4):1323-32. PubMed ID: 12684400
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A phase I clinical trial of murine monoclonal antibody D612 in patients with metastatic gastrointestinal cancer.
    Saleh MN; Khazaeli MB; Grizzle WE; Wheeler RH; Lawson S; Liu T; Russel C; Meredith R; Schlom J; LoBuglio AF
    Cancer Res; 1993 Oct; 53(19):4555-62. PubMed ID: 8402627
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunotherapy for recurrent colorectal cancers with human monoclonal antibody SK-1.
    Koda K; Glassy MC; McKnight ME; Yasutomi J; Saito N; Dan M; Nakajima N
    Anticancer Res; 2001; 21(1B):621-7. PubMed ID: 11299816
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer.
    Zonder JA; Shields AF; Zalupski M; Chaplen R; Heilbrun LK; Arlauskas P; Philip PA
    Clin Cancer Res; 2001 Jan; 7(1):38-42. PubMed ID: 11205915
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus.
    Davis JC; Totoritis MC; Rosenberg J; Sklenar TA; Wofsy D
    J Rheumatol; 2001 Jan; 28(1):95-101. PubMed ID: 11196549
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a phase I/II clinical trial.
    Kraeber-Bodéré F; Bardet S; Hoefnagel CA; Vieira MR; Vuillez JP; Murat A; Ferreira TC; Bardiès M; Ferrer L; Resche I; Gautherot E; Rouvier E; Barbet J; Chatal JF
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3190s-3198s. PubMed ID: 10541363
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Radioimmunotherapy of small cell lung carcinoma with the two-step method using a bispecific anti-carcinoembryonic antigen/anti-diethylenetriaminepentaacetic acid (DTPA) antibody and iodine-131 Di-DTPA hapten: results of a phase I/II trial.
    Vuillez JP; Kraeber-Bodéré F; Moro D; Bardiès M; Douillard JY; Gautherot E; Rouvier E; Barbet J; Garban F; Moreau P; Chatal JF
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3259s-3267s. PubMed ID: 10541373
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety, pharmacokinetics and pharmacodynamics of the anti-A33 fully-human monoclonal antibody, KRN330, in patients with advanced colorectal cancer.
    Infante JR; Bendell JC; Goff LW; Jones SF; Chan E; Sudo T; Burris HA; Berlin JD
    Eur J Cancer; 2013 Apr; 49(6):1169-75. PubMed ID: 23294608
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase Ia trial of murine immunoglobulin A antitransferrin receptor antibody 42/6.
    Brooks D; Taylor C; Dos Santos B; Linden H; Houghton A; Hecht TT; Kornfeld S; Taetle R
    Clin Cancer Res; 1995 Nov; 1(11):1259-65. PubMed ID: 9815920
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody.
    Deb N; Goris M; Trisler K; Fowler S; Saal J; Ning S; Becker M; Marquez C; Knox S
    Clin Cancer Res; 1996 Aug; 2(8):1289-97. PubMed ID: 9816299
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase I safety and pharmacokinetic study of bavituximab, a chimeric phosphatidylserine-targeting monoclonal antibody, in patients with advanced solid tumors.
    Gerber DE; Stopeck AT; Wong L; Rosen LS; Thorpe PE; Shan JS; Ibrahim NK
    Clin Cancer Res; 2011 Nov; 17(21):6888-96. PubMed ID: 21989064
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors.
    Herbst RS; Hong D; Chap L; Kurzrock R; Jackson E; Silverman JM; Rasmussen E; Sun YN; Zhong D; Hwang YC; Evelhoch JL; Oliner JD; Le N; Rosen LS
    J Clin Oncol; 2009 Jul; 27(21):3557-65. PubMed ID: 19546406
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts.
    Welt S; Divgi CR; Scott AM; Garin-Chesa P; Finn RD; Graham M; Carswell EA; Cohen A; Larson SM; Old LJ
    J Clin Oncol; 1994 Jun; 12(6):1193-203. PubMed ID: 8201382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.